Insider · CIK 0001498428

Cox John

Reports to the SEC for 5 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001498428

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-08	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−5,658 sh	$18.88	−$107K	357,507
2026-08-13	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−4,986 sh	$26.28	−$131K	363,165
2026-06-16	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−2,683 sh	$18.33	−$49.2K	368,151
2026-05-13	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−3,311 sh	$18.36	−$60.8K	370,834
2026-03-05	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−2,732 sh	$14.90	−$40.7K	374,145
2025-12-05	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−2,662 sh	$20.72	−$55.2K	196,877
2025-09-05	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−2,640 sh	$13.41	−$35.4K	199,539
2025-07-16	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Director, CEO & President	AAward	+197K sh	—	—	197,285
2025-07-15	DYNDyne Therapeutics, Inc.G Gift	Director, CEO & President	GGift	−10K sh	—	—	212,179
2025-07-15	DYNDyne Therapeutics, Inc.G Gift	Director, CEO & President	GGift	−10K sh	—	—	202,179
2025-07-15	DYNDyne Therapeutics, Inc.G Gift	Director, CEO & President	GGift	−10K sh	—	—	222,179
2025-07-15	DYNDyne Therapeutics, Inc.G Gift	Director, CEO & President	GGift	−10K sh	—	—	232,179
2025-07-14	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+100K sh	$9.11	+$911K	242,179
2025-06-05	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−4,060 sh	$13.35	−$54.2K	142,179
2025-03-05	DYNDyne Therapeutics, Inc.S Sale	Director, CEO & President	SSale	−4,061 sh	$11.83	−$48K	146,239
2024-12-04	DYNDyne Therapeutics, Inc.A Award	Director, CEO & President	AAward	+145K sh	—	—	150,300
2024-12-04	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Director, CEO & President	AAward	+232K sh	—	—	232,100
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+7,200 sh	$33.09	+$238K	8,000
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+800 sh	$32.57	+$26.1K	800
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+7,200 sh	$33.09	+$238K	8,000
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+800 sh	$32.57	+$26.1K	800
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+7,200 sh	$33.09	+$238K	8,000
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+800 sh	$32.57	+$26.1K	800
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+7,200 sh	$33.09	+$238K	8,000
2024-09-04	DYNDyne Therapeutics, Inc.P Purchase	Director, CEO & President	PPurchase	+800 sh	$32.57	+$26.1K	800
2024-03-25	DYNDyne Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, CEO & President	AAward	+680K sh	—	—	679,853
2023-08-11	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−683 sh	$5.00	−$3,413.907	0
2023-08-11	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−683 sh	$6.64	−$4,537.784	0
2023-08-11	Sigilon Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−341 sh	—	—	0
2023-05-19	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,888 sh	—	—	8,888
2022-05-26	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,888 sh	—	—	8,888
2021-06-24	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,888 sh	$9.97	+$88.6K	8,888
2020-12-08	Sigilon Therapeutics, Inc.C Conversion	Director	CConversion	+4,444 sh	—	—	4,444
2020-12-08	Sigilon Therapeutics, Inc.Series B-1 Convertible Preferred StockC Conversion	Director	CConversion	−4,444 sh	—	—	0
2020-03-24	RGENREPLIGEN CORPS Sale	Director	SSale	−1,858 sh	$96.72	−$180K	923
2020-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,632 sh	—	—	0
2020-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−14K sh	—	—	0
2020-03-18	RGENREPLIGEN CORPS Sale	Director	SSale	−1,016 sh	$97.17	−$98.7K	2,781
2020-03-18	RGENREPLIGEN CORPS Sale	Director	SSale	−1,187 sh	$96.45	−$114K	3,797
2020-03-18	RGENREPLIGEN CORPS Sale	Director	SSale	−24.5K sh	$95.13	−$2.33M	4,984
2020-03-18	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+3,304 sh	$42.07	+$139K	29,517
2020-03-18	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+3,366 sh	$26.12	+$87.9K	23,779
2020-03-18	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+2,434 sh	$38.76	+$94.3K	26,213
2020-03-18	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+3,632 sh	$41.19	+$150K	20,413
2020-03-18	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+14K sh	$12.91	+$181K	16,781
2020-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,304 sh	—	—	0
2020-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,434 sh	—	—	0
2020-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,366 sh	—	—	0
2020-03-04	RGENREPLIGEN CORPS Sale	Director	SSale	−10K sh	$93.39	−$934K	2,781
2020-03-04	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$12.91	+$129K	12,781

Recent filings

Accepted (ET)
Sep 84
Cox John0001498428-26-000005
SEC(opens sec.gov)
Aug 174
Cox John0001498428-26-000004
SEC(opens sec.gov)
Jun 174
Cox John0001498428-26-000002
SEC(opens sec.gov)
May 144
Cox John0001193125-26-223955
SEC(opens sec.gov)
Mar 64
Cox John0001193125-26-096512
SEC(opens sec.gov)
Dec 54
Cox John0001193125-25-309666
SEC(opens sec.gov)
Sep 94
Cox John0001498428-25-000003
SEC(opens sec.gov)
Jul 184
Cox John0000950170-25-097005
SEC(opens sec.gov)
Jul 154
Cox John0000950170-25-095929
SEC(opens sec.gov)
Jun 64
Cox John0000950170-25-083071
SEC(opens sec.gov)
Mar 74
Cox John0000950170-25-035495
SEC(opens sec.gov)
Dec 64
Cox John0000950170-24-134072
SEC(opens sec.gov)
Sep 44
Cox John0000950170-24-103533
SEC(opens sec.gov)

Companies

Address

C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD

WALTHAM, MA, 02451